TACE Combined With Lenvatinib and Sintilimab for Advanced HCC

Hepatocellular Carcinoma Non-resectable Clinical Trial

Official title:

Transcatheter Arterial Chemoembolization Combined With Lenvatinib and Sintilimab for Unresectable Advanced Hepatocellular Carcinoma: An Open-label, Single-arm, Single-center, Prospective Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04599790
• Other study ID #: MIIR-04
• Status: Completed
• Phase: Phase 2
• Start date: October 1, 2020
• Est. completion date: October 31, 2022

Study information

• Verified date: February 2022
• Source: Second Affiliated Hospital of Guangzhou Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and sintilimab in patients with unresectable advanced hepatocellullar carcinoma (HCC).

Description:

This is a Phase II study to evaluate the efficacy and safety of TACE combined with lenvatinib and sintilimab in patients with advanced HCC.

30 subjects with advanced HCC (Barcelona-Clinic- Liver-Cancer [BCLC] stage C, or China liver cancer staging [CNLC] IIIa and IIIb) will be enrolled in the study.

Lenvatinib 12mg (body weight ≥60kg) or 8mg (body weight <60kg) P.O. qd and sintilimab (200mg I.V. q3w) will be started at 3-7 days after the first TACE. TACE will be repeated if clinically indicated based on the evaluation of follow-up laboratory and imaging examination. Lenvatinib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Sintilimab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Patients will be allowed to have lenvatinib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: October 31, 2022
• Est. primary completion date: November 29, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Advanced HCC (BCLC stage C, or CNLC IIIa and IIIb ) with diagnosis confirmed by histology/cytology or clinically

• Disease not amenable to curative therapies but amenable to TACE

• At least one measurable untreated lesion

• No prior systemic therapy for HCC

• Child-Pugh score 5-7

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment

• Adequate organ and hematologic function

• Life expectancy of at least 3 months

• For women of childbearing potential and for men: agreement to remain abstinent

Exclusion Criteria:

• Diagnosis of fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC

• Diffuse HCC

• Portal vein tumor thrombus (PVTT) involves the main trunk and contralateral branch or upper mesenteric vein

• Inferior vena cava tumor thrombus

• Metastatic disease that involves major airways or blood vessels

• Symptomatic, untreated or progressing central nervous system metastasis

• Uncontrolled tumor-related pain

• Patients who received prior systemic therapy, immunotherapy, TACE, transcatheter arterial radioembolization (TARE), transcatheter arterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC) or radiation therapy for HCC

• Treatment with systemic immunostimulatory agents

• Use of herbal therapies or traditional Chinese medicines with anti-cancer activity within 2 weeks

• History of malignancy other than HCC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death

• Uncontrolled ascites, hydrothorax or pericardial effusion

• Prior esophageal and/or gastric varices bleeding within 6 months prior to initiation of study treatment

• Prior life-threatening blood loss or grade 3/4 gastrointestinal bleeding requiring blood infusion, endoscopic or surgical intervention within 3 months

• Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high-risk for bleeding

• History of gastrointestinal (GI) perforation and/or fistula in the past 6 months history of GI obstruction (including incomplete intestinal obstruction requiring parenteral nutrition), extensive bowel resection (partial colectomy or extensive small bowel resection, complicated by chronic diarrhea), Crohn's disease, ulcerative colitis or long-term chronic diarrhea

• History of hepatic encephalopathy

• History of organ and stem cell transplantation

• Long-term daily treatment with a non-steroidal anti-inflammatory drug (NSAID)

• Use of immunosuppressive drugs in the past 4 weeks, excluding the routes of topical glucocorticoids or physiological doses of systemic glucocorticoids (ie no more than 10 mg/day of prednisone or equivalent). Temporary use of glucocorticoids for dyspnea symptoms such as asthma and chronic obstructive pulmonary disease is allowed

• History of idiopathic pulmonary fibrosis, interstitial pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis

• Active tuberculosis

• Active severe infection; use of antibiotics within 2 weeks prior to injection of tislelizumab

• Autoimmune disease or immune deficiency

• Inadequately controlled hypertension; history of hypertensive crisis or hypertensive encephalopathy

• Bleeding diathesis or significant coagulopathy

• Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture underwent major surgery (craniotomy, thoracotomy or open surgery) within 4 weeks; non-recovery from side effects of these procedure

• History of venous thromboembolism in the past 6 months, but implantable IV ports or catheter-derived thrombosis, superficial venous thrombosis, or thrombosis after conventional anticoagulant therapy are excluded

• Current or recent use of aspirin or treatment with dipyramidole, ticlopidine, clopidogrel, or cilostazol uncontrolled metabolic disorder, non-malignant organ or systemic disease or secondary carcinomatous reaction, with high medical risk and/or uncertainty of life expectancy evaluation

• Other acute or chronic diseases, mental illness, or abnormal laboratory test results that may lead to the following outcomes: increase the risk of participating in study or study drug administration, or interfere with the interpretation of the study results and considered by investigator as "NOT" eligible to participate in this study

• Female patients who are pregnancy or breastfeeding

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma Non-resectable

Intervention

Drug:
• TACE combined with lenvatinib and sintilimab
Lenvatinib 12mg (body weight =60kg) or 8mg (body weight <60kg) P.O. qd and sintilimab 200mg I.V. q3w will be started at 3-7 days after the first TACE.TACE will be repeated if clinically indicated. Treatment of sintilimab will last up to 24 months. Patients will be allowed to have lenvatilib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.

Locations

Country	Name	City	State
China	The Second Affiliated Hospital of Guangzhou Medical University	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Second Affiliated Hospital of Guangzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival (PFS) assessed by investigators according to Modified RECIST (mRECIST)	The time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first.	24 months
Secondary	Adverse Events (AEs)	Number of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), AE of special interest (AESI), serious adverse event (SAE), assessed by NCI CTCAE v5.0.	24 months
Secondary	Progression free survival (PFS) assessed by investigators according to Response Evalutaion Criteria in Solid Tumors (RECIST) v1.1 and immune-related RECIST (irRECIST).	The time from initiation of treatment until the first occurrence of disease progression or death from any cause, whichever occurs first.	24 months
Secondary	Objective response rate (ORR) assessed by investigators according to RECIST 1.1 and irRECIST.	The percentage of patients who had a best overall tumor response rating of complete response (CR) or partial response (PR).	24 months
Secondary	Disease control rate (DCR) assessed by investigators according to RECIST 1.1 and irRECIST.	The percentage of patients who had a tumor response rating of CR, PR, or stable disease (SD).	24 months
Secondary	Duration of response (DOR) assessed by investigators according to RECIST 1.1 and irRECIST.	The time from the first occurrence of a documented objective response to disease progression (PD) or death.	24 months
Secondary	Overall survival (OS)	The time from initiation of treatment until the date of death from any cause.	24 months
Secondary	ORR assessed by investigators according to mRECIST.	The percentage of patients who had a best overall tumor response rating of CR or PR.	24 months
Secondary	DCR assessed by investigators according to mRECIST.	The percentage of patients who had a tumor response rating of CR, PR, or SD.	24 months
Secondary	DOR assessed by investigators according to mRECIST.	The time from the first occurrence of a documented objective response to PD or death.	24 months